Abstract
Glucokinase hyperinsulinism is a rare variant of congenital hyperinsulinism caused
by activating mutations in the glucokinase gene and has been reported so far to be
a result of overactivity of glucokinase within the pancreatic β-cell. Here we report
on a new patient with difficulties to diagnose persistent hyperinsulinism and discuss
diagnostic procedures of this as well as the other reported individuals. After neonatal
hypoglycemia, the patient was reevaluated at the age of 3 years for developmental
delay. Morning glucose after overnight fast was 2.5–3.6 mmol/l. Fasting tests revealed
supressed insulin secretion at the end of fasting (1.4–14.5 pmol/l). In addition,
diagnostic data of the patients reported so far were reviewed. A novel heterozygous
missense mutation in exon 10 c.1354G>C (p.Val452Leu) was found and functional studies
confirmed the activating mutation. There was no single consistent diagnostic criterion
found for our patient and glucokinase hyperinsulinism individuals in general. Often
at the time of hypoglycemia low insulin levels were found. Therefore insulin concentrations
at hypoglycemia, or during fasting test as well as reactive hypoglycemia after an
oral glucose tolerance test were not conclusive for all patients. A glucose lowering
effect in extra-pancreatic tissues independent from hyperinsulinism that results in
diagnostic difficulties may contribute to underestimation of glucokinase hyperinsulinism.
Mutational analysis of the GCK-gene should be performed in all individuals with unclear
episodes of hypoglycemia even without documented hyperinsulinism during hypogly-cemia.
Delay of diagnosis might result in mental handicap of the affected individuals.
Key words
congenital hyperinsulinism - monogenic hyperinsulinism - glucokinase - glucose stimulated
insulin secretion (GSIS)
References
1
Meissner T, Beinbrech B, Mayatepek E.
Congenital hyperinsulinism: molecular basis of a heterogeneous disease.
Hum Mutat.
1999;
13
351-361
2
Lindley KJ, Dunne MJ.
Contemporary strategies in the diagnosis and management of neonatal hyperinsulinaemic
hypoglycaemia.
Early Hum Dev.
2005;
81
61-72
3
Aynsley-Green A, Hussain K, Hall J, Saudubray JM, Nihoul-Fekete C, Lonlay-Debeney P
De, Brunelle F, Otonkoski T, Thornton P, Lindley KJ.
Practical management of hyperinsulinism of infancy.
Arch Dis Child Fetal Neonatal.
2000;
82
98-107
4
Thomas PM, Cote GJ, Wohllk N, Haddad B, Mathew PM, Rabl W, Aguilar-Bryan L, Gagel RF,
Bryan J.
Mutations in the sulfonylurea receptor gene in familial hyperinsulinemic hypoglycemia
of infancy.
Science.
1995;
268
426-429
5
Nestorowicz A, Inagaki N, Gonoi T, Schoor KP, Wilson BA, Glaser B, Landau H, Stanley CA,
Thornton PS, Seino S, Permutt MA.
A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated
with familial hyperinsulinism.
Diabetes.
1997;
46
1743-1748
6
Stanley CA, Lieu YK, Hsu BY, Ming JE, Glaser B, Poncz M.
Hyperin-sulinism and hyperamonemia in infants with regulatory mutations of the glutamate
dehydrogenase gene.
N Engl J Med.
1998;
338
1352-1357
7
Clayton PT, Eaton S, Aynsley-Green A, Edginton M, Hussain K, Krywawych S, Datta V,
Malingré HEM, Berger R, Berg IET van den.
Hyperinsulinism in short-chain l-3-hydroxyacyl-CoA dehydrogenase deficiency reveals
the importance of β-oxidation in insulin secretion.
J Clin Invest.
2001;
108
457-465
8
Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, Stanley CA, Thornton PS,
Permutt MA, Matschinsky FM, Herold HC.
Familial hyperinsulinism caused by an activating glucokinase mutation.
N Engl J Med.
1998;
338
226-230
9
Christesen HB, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A, Hansen T, Brusgaard K,
Massa O, Magnuson MA, Shiota C, Matschinsky FM, Barbetti F.
The second activating glucokinase mutation (A456 V): implications for glucose homeostasis
and diabetes therapy.
Diabetes.
2002;
51
1240-1246
10
Gloyn AL, Noordam K, Willemsen MA, Ellard S, Lam WW, Campbell IW, Midgley P, Shiota C,
Buettger C, Magnuson MA, Matschinsky FM, Hattersley AT.
Insights into the biochemical and genetic basis of glucokinase activation from naturally
occurring hypoglycemia mutations.
Diabetes.
2003;
52
2433-2434
11
Cuesta-Munoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Nanto-Salonen K, Rahier J,
Lopez-Enriquez S, Garcia-Gimeno MA, Sanz P, Soriguer FC, Laakso M.
Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation.
Diabetes.
2004;
53
2164-2168
12
Dullaart RP, Hoogenberg K, Rouwe CW, Stulp BK.
Family with autosomal dominant hyperinsulinism associated with A456V mutation in the
glucokinase gene.
J Intern Med.
2004;
255
143-145
13
Wabitsch M, Lahr G, Bunt M Van de, Marchant C, Lindner M, Puttkamer J von, Fenneberg A,
Debatin KM, Klein R, Ellard S, Clark A, Gloyn AL.
Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation
causing persistent hyperinsulinaemic hypoglycaemia of infancy.
Diabet Med.
2007;
24
1393-1399
14
Christesen HB, Tribble ND, Molven A, Siddiqui J, Sandal T, Brusgaard K, Ellard S,
Njølstad PR, Alm J, Brock Jacobsen B, Hussain K, Gloyn AL.
Activating glucokinase (GCK) mutations as a cause of medically responsive congenital
hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation.
Eur J Endocrinol.
2008;
159
27-34
15
Duvanel CB, Fawer CL, Cotting J, Hohlfeld P, Matthieu JM.
Long-term effects of neonatal hypoglycemia on brain growth and psychomotor development
in small-for-gestational-age preterm infants.
J Pediatr.
1999;
134
492-498
16
Matschinsky FM.
Regulation of pancreatic β-cellglucokinase: from basics to therapeutics.
Diabetes.
2002;
51
394-404
17
Davis EA, Cuesta-Munoz A, Raoul M, Buettger C, Sweet I, Moates M, Magnuson MA, Matschinsky FM.
Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their
analysis illuminates fundamental quantitative concepts of glucose homeostasis.
Diabetologia.
1999;
42
1175-1186
18
Froguel P, Zouali H, Vionnet N, Velho G, Vdaire M, Sun F, Lesage S, Stoffel M, Takeda J,
Passa P, Permutt A, Beckmann JS, Bell GI, Cohen D.
Familial hyperglycemia due to mutations in glucokinase.
N Engl J Med.
1993;
328
697-702
19
Njolstad PR, Sovic O, Cuesta-Munoz A, Bjorkhaug L, Massa O, Barbetti F, Undlien DE,
Shiota C, Magnuson MA, Molven A, Matschinsky FM, Bell GI.
Neonatal diabetes mellitus due to complete glucokinase deficiency.
N Engl J Med.
2001;
344
1588-1592
20
Matschinsky FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, Han Y, Taub R, Grimsby J.
The network of glucokinase-expressing cells in glucose homeostasis and the potential
of glucokinase activators for diabetes therapy.
Diabetes.
2006;
55
1-12
Correspondence
T. Meissner
Department of General Pediatrics
University Children's Hospital
Moorenstr. 5
40225 Düsseldorf
Germany
Phone: +49/211/811 76 38
Fax: +49/211/811 95 12
Email: thomas.meissner@med.uni-duesseldorf.de
A. L. Cuesta-MuñozMD, PhD
IMABIS Foundation and Center
for the Study of Pancreatic
Beta-cell Diseases Carlos
Haya University Hospital
Avda. Carlos Haya no 82
29010 Málaga
Spain
Phone: 34/95/129 14 46
Fax: 34/95/261 40 12
Email: alcm@fundacionimabis.org